Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...